CORRECTION FROM SOURCE: Theranexus and BBDF Win FDA Approval on Efficacy ...
CORRECTION FROM SOURCE: Theranexus and BBDF Win FDA Approval on Efficacy ...
Source: pr-inside.com
📰 Mathieu Charv News
Page 2 - Mathieu Charv News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mathieu Charv. Real-time updates on events, politics, business and more.
Lyon, France – 12 April 2023 – 6pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug... | April 12, 2023
Source: marketscreener.com
THERANEXUS PUBLISHES ITS 2022 FULL-YEAR RESULTS AND PRESENTS AN UPDATE ON ITS PROGRAMS
Lyon, France - 12 April 2023 - 6pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating
United States France General Florence Portejoie Thierry Lambert Worldsymposium Orlando Martin Pierre Laurent
Source: finanznachrichten.de
Theranexus, BBDF and Cardiff University Present Their Novel Research on Batten-1 and Batten Disease at WORLDSymposium 2023
From 22 to 26 February 2023 in Orlando, Florida Presentation of preclinical data demonstrating how Batten-1 drastically reduces the buildup of toxic glycosphingolipids in Batten disease and a poster
Source: finanznachrichten.de
THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023
From 22 to 26 February 2023 in Orlando, Florida Presentation of preclinical data demonstrating how Batten-1 drastically reduces the buildup of toxic glycosphingolipids in Batten disease and a poster
Source: finanznachrichten.de
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES
Lyon, France - 18 January 2023 - 7.30am CET - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating
France General Thierry Lambert Inserm Transfert Mathieu Charv Franck Mouthon Mathieu Florence Portejoie
Source: finanznachrichten.de
THERANEXUS AND BBDF PRESENT PROGRESS ON THE BATTEN-1 PROGRAM AT THE TRANSLATIONAL RESEARCH CONFERENCE FOR THE MANAGEMENT OF NCLS ON 3 AND 4 NOVEMBER, 2022 IN CHICAGO
Lyon, France - Austin, Texas, United States - 2 November 2022 - 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development
Source: finanznachrichten.de
THERANEXUS: THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS
Lyon, France - 9 June 2022- 6 pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the
San Diego United States France General Haute Normandie Mathieu Charv Federation Of European Neuroscience Societies
Source: finanznachrichten.de
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating
United States France General Mathieu Charv Franck Mouthon Innovative Young Company Research Tax Credit
Source: sharewise.com
THERANEXUS: THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
· New milestone for NeuroLead, the active agent screening platform · New publications in scientific journals · Start of Phase I/II clinical trial for Batten disease Lyon, 28 February 2022 -
Source: finanznachrichten.de